WO2023012669 - BIOPHARMACEUTICAL COMPOSITIONS AND STABLE ISOTOPE LABELING PEPTIDE MAPPING METHOD
National phase entry:
Publication Number
WO/2023/012669
Publication Date
09.02.2023
International Application No.
PCT/IB2022/057173
International Filing Date
02.08.2022
Title **
[English]
BIOPHARMACEUTICAL COMPOSITIONS AND STABLE ISOTOPE LABELING PEPTIDE MAPPING METHOD
[French]
COMPOSITIONS BIOPHARMACEUTIQUES ET PROCÉDÉ DE CARTOGRAPHIE PEPTIDIQUE DE MARQUAGE ISOTOPIQUE STABLE
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
GSK Medicines Research Centre
Gunnels Wood Road
Stevenage SG1 2NY, GB
Inventors
DAVIS, Tyler Keith
1250 S Collegeville Rd
Collegeville, Pennsylvania 19426, US
SCHUESSLER, Hillary Amber
1250 S Collegeville Rd
Collegeville, Pennsylvania 19426, US
Priority Data
63/228,951
03.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2427 | |
| EPO | Filing, Examination | 15769 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 12110 |
Total: 31472 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed herein are stable isotope labeling (SIL) peptide mapping methods for accurate and sensitive conjugation site quantitation. Also disclosed herein are compositions comprising antibody drug conjugates (ADCs) that target BCMA.[French]
L'invention concerne des procédés de cartographie peptidique de marquage isotopique stable (SIL) pour une quantification précise et sensible d'un site de conjugaison. L'invention concerne également des compositions comprenant des conjugués anticorps-médicament (ADC) ciblant BCMA.